Evidence map›Paper›PMID 42871568›Full record

ReviewJournal of diabetes and metabolic disorders2026

The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.

Zhiyu Chen, Ying Zhou, Gang Li, AbdulRahman Muthanna, Annette d'Arqom, Chau Ling Tham, Yu-Cheng Ho, Ming Tatt Lee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhiyu ChenDepartment of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, Inner Mongolia, Hohhot, 010017 China.
Ying ZhouDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034 China.
Gang LiOffice of Postgraduate Studies, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010110 China.
AbdulRahman MuthannaOffice of Postgraduate Studies, UCSI University, Kuala Lumpur, 56000 Malaysia.
Annette d'ArqomDepartment of Anatomy, Histology, and Pharmacology, Faculty of Medicine, Universitas Airlangga, 60115 Surabaya, Indonesia.
Chau Ling ThamDepartment of Biomedical Sciences, Universiti Putra Malaysia, Selangor, 43200 Malaysia.
Yu-Cheng HoSchool of Medicine, College of Medicine, I-Shou University, No.8, Yida Rd., Yanchao District, Kaohsiung City, 82445 Taiwan.
Ming Tatt LeeFaculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, 56000 Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity significantly increases the risk of developing other chronic diseases and shortens the life expectancy by 5 to 8 years. Childhood obesity is particularly prominent as 80% of teenagers with obesity have shown it to persist into adulthood. With reference to the development of adult medication, the present review summarises the recent research progress in the development of pediatric anti-obesity drugs. The current management guidelines support the use of medication for adolescents aged 12 and above when lifestyle measures are ineffective. Early weight-loss drugs like the serotonergic agonist fenfluramine and the norepinephrine reuptake inhibitor sibutramine were withdrawn due to severe safety issues. Rainbow pills and the CB Graphical abstract:

Indexed as

Childhood obesityGLP-1 agonistGood health and wellbeingWeight management

Identifiers

PMID42871568
PMCPMC13658666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.